The Cardio Diabetes Master Class was a dynamic meeting with state of the art lectures, clinical debates and practical workshops. Participants are part of an ongoing educational initiative that support clinicians in their daily clinical management of cardiovascular risk and diabetes. As an educational service teaching slides  developed and presented by faculty are available to view and download for participants

The program of this Master Class, entitled:
 

T2DM management in high CV risk patients: What are the Facts and Opportunities?

was designed to provide the participants with new information and perspectives on effective strategies to help patients, with diabetes and/or increased cardiovascular risk to reach their treatment goals.
 

The educational objectives of the program were:

• To explore mechanisms and common pathways underlying the development of cardiovascular disease and diabetes
• To review and discuss the importance of glucose management and the rationale for early intervention strategies in patients with diabetes
• To discuss the role of anti-diabetic therapy, in particular the use of DPP4 inhibitors and TZD’s, in a riskbased intervention strategy that targets glucose control and cardiovascular risk factors
• To discuss therapies that work through other insulin-related mechanisms, including insulin resistance in order to reduce the incidence of cardiovascular events; especially in high-risk patient populations with a history of an ACS event and multiple risk factors
• To evaluate the current guidelines for the management of patients with diabetes and high CV risk, and identify potential novel targets for therapy in this high-risk patient group
• To discuss current and future strategies for practical management and interventions to prevent cardiovascular events in multirisk patients

 

CME Accreditation

CME accreditation was accredited by the European Board for accreditation in Cardiology (EBAC) with
endorsement of the Gulf Heart Association.
 

Funding

The programme is funded by an unrestricted educational grant provided by Takeda Pharmaceuticals
 

Meeting resources (more to follow)

 

Webcasts

  3 minute education • 6-5-2016, Dubai, UAE, Dr Robert J Chilton

Stroke reduction with PPAR-Y antagonist pioglitazone

Dr. Robert Chilton, (Texas) discusses the results of the IRIS trial where treatment with PPAR-γ agonist pioglitazone

3 minute education • 6-5-2016, Dubai, UAE, Dr Sanjay Rajagopalan, MD, Maryland

Review of cardiovascular safety of DPP4 inhibitors

Dr Rajagopalan, MD, Maryland, USA reviews the utility of DPP4 inhibitors in T2DM patients with high risk CVD

Teaching slides

 

Are new DPP4 Outcome trials changing the fundamentals of diabetes management?

Presentation prepared and held by dr Sanjay Rajagopalan, Maryland, USA at the CME accredited 'Cardio Diabetes Master Class' held on April 15-16, 2016 in Dubai, UAE.
 

Understanding the natural course of diabetes and CVD

Presentation prepared and held by Prof Kausik Ray, Imperial College London at the CME accredited 'Cardio Diabetes Master Class' held on April 15-16, 2016 in Dubai, UAE.
 

New updates on PPARs and the diabetes heart

Presentation prepared and held by Prof Robert Chilton, San Antonio, Texas, USA at the CME accredited 'Cardio Diabetes Master Class' held on April 15-16, 2016 in Dubai, UAE

Lectures

Understanding the natural course of diabetes and CVD Prof Kausik Ray, MD, Imperial College London, UK

The burden of diabetes in the Gulf: A call for action? Tarek Mohamed Fiad, MD - Sheik Khalifa Medical City Abu Dhabi, UAE

Preservation of beta cell function vs improving insulin resistance; What are the ideal drugs ? Dr. Iyad Ksseiry, M.D. Dubai, UAE

Are new DPP4 Outcome trials changing the fundamentals of diabetes management? Sanjay Rajagopalan, MD - Maryland, USA

New updates on PPARs and the diabetes heart Robert J. Chilton, MD, San Antonio, Texas, USA